Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110019/S141

XIENCE Alpine, XIENCE Sierra, XIENCE PRO S, and XIENCE Skypoint Everolimus Eluting Coronary Stent Systems

Abbott Vascular · Decision date May 22, 2026

FDA DECISIONP110019/S141

What did the FDA decide?

FDA records P110019/S141 as a supplement to PMA P110019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 22, 2026.

FDA approval order statement

reduced confirmatory testing of Everolimus BHT reference standard
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
May 22, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P110019/S141
Regulatory pathway
PMA supplement
Product code
NIQ
Decision code
OK30
Decision date
May 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Product code
NIQ
FDA device class
3

For the original device and its historical approval scope, see PMA P110019. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P110019 · Original PMA

    Xience Skypoint Everolimus Eluting Coronary Stent System

  2. P110019/S136 · Related supplement

    XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine); XIENCE Sierra Everolimus Eluting Coronary Sten

  3. P110019/S137 · Related supplement

    XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine OTW)

  4. P110019/S138 · Related supplement

    XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine), XIENCE Sierra Everolimus Eluting Coronary Stent

  5. P110019/S139 · Related supplement

    XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine); XIENCE Sierra Everolimus Eluting Coronary Stent

  6. P110019/S140 · Related supplement

    XIENCE Alpine Everolimus Eluting Coronary Stent System; XIENCE Sierra Everolimus Eluting Coronary Stent System; XIENCE P

  7. P110019/S141 received

    Application receipt date recorded by FDA.

  8. P110019/S141 · FDA decision

    30-Day Notice

  9. P110019/S142 · Related supplement

    XIENCE Alpine; XIENCE Sierra; XIENCE PROs; XIENCE Skypoint Everolimus Eluting Coronary Stent Systems

  10. P110019/S144 · Related supplement

    XIENCE PROS Everolimus Eluting Coronary Stent System (XIENCE PRO5); XIENCE Skypoint Everolimus Eluting Coronary Stent Sy

  11. P110019/S145 · Related supplement

    XIENCE PRO5 Everolimus Eluting Coronary Stent System (XIENCE PRO5), XIENCE Skypoint Everolimus Eluting Coronary Stent Sy

Timeline entries are records held by MedtechLedger for P110019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110019

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Vascular

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3200 Lakeside Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records